QQQ   311.72 (+3.59%)
AAPL   150.82 (+3.71%)
MSFT   264.60 (+4.69%)
META   188.77 (+23.28%)
GOOGL   107.74 (+7.28%)
AMZN   112.91 (+7.38%)
TSLA   188.27 (+3.78%)
NVDA   217.09 (+3.66%)
NIO   11.96 (-1.16%)
BABA   109.74 (-2.73%)
AMD   88.31 (+4.34%)
T   20.28 (+0.50%)
MU   63.17 (+0.91%)
F   14.32 (+3.84%)
CGC   3.14 (+1.95%)
GE   83.94 (+1.97%)
DIS   113.21 (+3.49%)
AMC   6.08 (+6.48%)
PFE   44.34 (+0.84%)
PYPL   86.96 (+4.88%)
NFLX   366.89 (+1.35%)
QQQ   311.72 (+3.59%)
AAPL   150.82 (+3.71%)
MSFT   264.60 (+4.69%)
META   188.77 (+23.28%)
GOOGL   107.74 (+7.28%)
AMZN   112.91 (+7.38%)
TSLA   188.27 (+3.78%)
NVDA   217.09 (+3.66%)
NIO   11.96 (-1.16%)
BABA   109.74 (-2.73%)
AMD   88.31 (+4.34%)
T   20.28 (+0.50%)
MU   63.17 (+0.91%)
F   14.32 (+3.84%)
CGC   3.14 (+1.95%)
GE   83.94 (+1.97%)
DIS   113.21 (+3.49%)
AMC   6.08 (+6.48%)
PFE   44.34 (+0.84%)
PYPL   86.96 (+4.88%)
NFLX   366.89 (+1.35%)
QQQ   311.72 (+3.59%)
AAPL   150.82 (+3.71%)
MSFT   264.60 (+4.69%)
META   188.77 (+23.28%)
GOOGL   107.74 (+7.28%)
AMZN   112.91 (+7.38%)
TSLA   188.27 (+3.78%)
NVDA   217.09 (+3.66%)
NIO   11.96 (-1.16%)
BABA   109.74 (-2.73%)
AMD   88.31 (+4.34%)
T   20.28 (+0.50%)
MU   63.17 (+0.91%)
F   14.32 (+3.84%)
CGC   3.14 (+1.95%)
GE   83.94 (+1.97%)
DIS   113.21 (+3.49%)
AMC   6.08 (+6.48%)
PFE   44.34 (+0.84%)
PYPL   86.96 (+4.88%)
NFLX   366.89 (+1.35%)
QQQ   311.72 (+3.59%)
AAPL   150.82 (+3.71%)
MSFT   264.60 (+4.69%)
META   188.77 (+23.28%)
GOOGL   107.74 (+7.28%)
AMZN   112.91 (+7.38%)
TSLA   188.27 (+3.78%)
NVDA   217.09 (+3.66%)
NIO   11.96 (-1.16%)
BABA   109.74 (-2.73%)
AMD   88.31 (+4.34%)
T   20.28 (+0.50%)
MU   63.17 (+0.91%)
F   14.32 (+3.84%)
CGC   3.14 (+1.95%)
GE   83.94 (+1.97%)
DIS   113.21 (+3.49%)
AMC   6.08 (+6.48%)
PFE   44.34 (+0.84%)
PYPL   86.96 (+4.88%)
NFLX   366.89 (+1.35%)
NASDAQ:ALLO

Allogene Therapeutics - ALLO Price Target & Analyst Ratings

$8.21
+0.24 (+3.01%)
(As of 02/2/2023 12:00 AM ET)
Add
Compare
Today's Range
$8.04
$8.40
50-Day Range
$5.62
$10.77
52-Week Range
$5.41
$17.49
Volume
1.81 million shs
Average Volume
2.01 million shs
Market Capitalization
$1.18 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.27

Allogene Therapeutics Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 11 Analyst Ratings

Consensus Analyst Price Target

$20.27
146.93% Upside
High Prediction$32.00
Average Prediction$20.27
Low Prediction$9.00
TypeCurrent
2/2/22 to 2/2/23
1 Month Ago
1/3/22 to 1/3/23
3 Months Ago
11/4/21 to 11/4/22
1 Year Ago
2/2/21 to 2/2/22
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
9 Buy rating(s)
6 Buy rating(s)
7 Buy rating(s)
12 Buy rating(s)
Hold
1 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$20.27$23.10$27.10$35.00
Predicted Upside146.93% Upside116.38% Upside135.65% Upside66.90% Upside
Get Allogene Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ALLO and its competitors with MarketBeat's FREE daily newsletter.


ALLO Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ALLO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Allogene Therapeutics Stock vs. The Competition

TypeAllogene TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.73
2.65
2.46
Consensus RatingModerate BuyBuyHold
Predicted Upside151.52% Upside1,297.15% Upside7.40% Upside
News Sentiment RatingPositive News
Positive News
Neutral News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
1/24/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Overweight$20.00 ➝ $11.00+60.35%
1/6/2023Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Outperform$12.00+106.54%
1/5/2023EF Hutton Acquisition Co. I
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$15.00+158.62%
12/12/2022Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Underperform$24.00 ➝ $9.00+2.74%
12/1/2022Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$32.00+234.03%
11/21/2022HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$43.00 ➝ $29.00+183.20%
9/27/2022JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reni Benjamin
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$23.00+100.17%
9/22/2022B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$21.00 ➝ $18.00+56.11%
8/23/2022Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$29.00+94.11%
8/10/2022Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform
7/15/2022The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$9.00 ➝ $32.00+169.81%
3/29/2022William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
R. Prasad
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
1/4/2022Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$40.00 ➝ $35.00+142.05%
12/14/2021Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$45.00 ➝ $35.00+148.05%
10/20/2021Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform
10/8/2021Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Biren Amin
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy
10/8/2021Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetHold ➝ Buy$60.00 ➝ $35.00+43.56%
10/8/2021Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$44.00 ➝ $18.00-26.17%
6/8/2020SunTrust Banks
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Asthika Goonewardene
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetHold$32.00 ➝ $50.00+15.74%
5/29/2020Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight$50.00 ➝ $70.00+50.21%
2/24/2020Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageHold$27.00+3.81%
(Data available from 2/2/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












ALLO Price Target - Frequently Asked Questions

What is Allogene Therapeutics's consensus rating and price target?

According to the issued ratings of 11 analysts in the last year, the consensus rating for Allogene Therapeutics stock is Moderate Buy based on the current 1 sell rating, 1 hold rating and 9 buy ratings for ALLO. The average twelve-month price prediction for Allogene Therapeutics is $20.27 with a high price target of $32.00 and a low price target of $9.00. Learn more on ALLO's analyst rating history.

Do Wall Street analysts like Allogene Therapeutics more than its competitors?

Analysts like Allogene Therapeutics more than other Medical companies. The consensus rating for Allogene Therapeutics is Moderate Buy while the average consensus rating for medical companies is Buy. Learn more on how ALLO compares to other companies.

Is Allogene Therapeutics being upgraded or downgraded by Wall Street analysts?

Over the previous 90 days, Allogene Therapeutics's stock had 2 upgrades and 1 downgrade by analysts.

Does Allogene Therapeutics's stock price have much upside?

According to analysts, Allogene Therapeutics's stock has a predicted upside of 115.40% based on their 12-month price targets.

What analysts cover Allogene Therapeutics?

Allogene Therapeutics has been rated by Bank of America, EF Hutton Acquisition Co. I, HC Wainwright, JPMorgan Chase & Co., Oppenheimer, and Robert W. Baird in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:ALLO) was last updated on 2/2/2023 by MarketBeat.com Staff